- Sanofi SA SNY elected to terminate its second amended and restated collaboration and license agreement with Regulus Therapeutics Inc RGLS, initially announced in 2014.
- In July 2022, Sanofi decided to terminate the Phase 2 clinical study of lademirsen for Alport syndrome for failure to meet Sanofi’s pre-defined futility criteria.
- Safety issues forced a revamp of that late-stage program when Sanofi flagged a failure for its microRNA drug lademirsen.
- At that time, Sanofi was evaluating other opportunities for the program in other indications. The decision to terminate the study did not stem from any safety issues. The termination will become effective on February 5, 2023.
- Lademirsen was the only product candidate from the collaboration advanced against miR-21 into the clinic.
- In addition, Sanofi had opt-in rights to a preclinical program targeting miR-221/222 for oncology indications.
- Regulus was eligible to receive $25.0 million in further development milestone payments if the Phase 2 study of lademirsen achieved its primary clinical endpoint or upon Sanofi’s election to advance the program into later stages of clinical development.
- In addition, if Sanofi exercised its opt-in rights to the miR221/222 program, Regulus was eligible to receive milestone payments of up to $38.8 million for proof-of-concept option exercise fees, $25.0 million for clinical milestones and up to $130.0 million for regulatory and commercial milestones.
- Price Action: RGLS shares closed at $1.40 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
